%0 Journal Article
%A Santoro, Francesco
%A Nunez-Gil, Ivan Javier
%A Vitale, Enrica
%A Viana-Llamas, Maria C.
%A Reche-Martinez, Begona
%A Romero-Pareja, Rodolfo
%A Feltez Guzman, Gisela
%A Fernandez Rozas, Inmaculada
%A Uribarri, Aitor
%A Becerra-Munoz, Victor Manuel
%A Alfonso-Rodriguez, Emilio
%A Garcia-Aguado, Marcos
%A Huang, Jia
%A Ortega-Armas, Maria Elizabeth
%A Garcia Prieto, Juan F.
%A Corral Rubio, Eva Maria
%A Ugo, Fabrizio
%A Bianco, Matteo
%A Mulet, Alba
%A Raposeiras-Roubin, Sergio
%A Jativa Mendez, Jorge Luis
%A Espejo Paeres, Carolina
%A Albarran, Adrian Rodriguez
%A Marin, Francisco
%A Guerra, Federico
%A Akin, Ibrahim
%A Cortese, Bernardo
%A Ramakrishna, Harish
%A Macaya, Carlos
%A Fernandez-Ortiz, Antonio
%A Brunetti, Natale Daniele
%T Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
%D 2021
%@ 1355-6037
%U https://hdl.handle.net/10668/26896
%X Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival.Methods 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient.Results During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74 +/- 12 years vs 63 +/- 17 years, p
%K COVID-19
%K pharmacology
%K clinical
%K Coronavirus disease 2019
%~